The efficacy of PSA screening: impact of key components in the ERSPC and PLCO trial

BACKGROUND: The European Randomized Study of Screening for Prostate Cancer (ERSPC) showed that prostate-specific antigen (PSA) screening significantly reduced prostate cancer mortality (rate ratio (RR)=0.79, 95%CI 0.69–0.91). The U.S. Prostate, Lung, Colorectal, and Ovarian (PLCO) trial showed no su...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Cancer
Huvudupphovsmän: de Koning, Harry J, Gulati, Roman, Moss, Sue M, Hugosson, Jonas, Pinsky, Paul F, Berg, Christine D, Auvinen, Anssi, Andriole, Gerald L, Roobol, Monique J, Crawford, E. David, Nelen, Vera, Kwiatkowski, Maciej, Zappa, Marco, Luján, Marcos, Villers, Arnauld, de Carvalho, Tiago M, Feuer, Eric J, Tsodikov, Alex, Mariotto, Angela B, Heijnsdijk, Eveline AM, Etzioni, R
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2017
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5839977/
https://ncbi.nlm.nih.gov/pubmed/29211316
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.31178
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk